Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, will share data about its groundbreaking mNGS test, Delve Detect, at the 2025 American Academy of Neurology Annual Meeting today in San Diego. With the ability to identify more than 68,000 pathogens with a single test, Delve's mNGS technology delivers greater diagnostic yield over conventional methods of diagnosing meningitis and encephalitis.
'Diagnosing meningitis and encephalitis has historically required running test after test as physicians try to determine which pathogen is causing a patient's infection. In more than half of those cases, the cause is never found,' said Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'By using a metagenomic test, clinicians can detect viruses, bacteria, parasites, and fungi in just one test. It's an approach with more than seven years of real world evidence behind it showing mNGS outperforms traditional testing methods by over 20%, helping solve complex cases faster.'
At this year's AAN Annual Meeting, Delve is presenting its mNGS assay and the technology behind Delve Detect. The backbone of Delve's mNGS platform is Delve Decide, which enables sequence matching of DNA and RNA to a curated database of over 68,000 pathogens through robust bioinformatic analysis, validated QC metrics, dynamic filtering, and visualization of high-quality reads; the results receive expert clinical interpretation to deliver comprehensive microbial analysis impossible through conventional testing.
The strength of Delve's approach has been demonstrated through data from more than 4,800 patients tested at the University of California San Francisco (UCSF) over seven years – the largest study of its kind. The study found mNGS identified more pathogens than all other traditional methods (culture, antigen testing, PCR, and serology) combined. Published in Nature Medicine, the data showed mNGS detected pathogens in 14.4% of samples, representing 437 unique pathogen species, including DNA and RNA viruses, bacteria, fungi, and parasites. Among a subset of more than 1,000 patients treated at UCSF, 21.8% (48 of 220) of infections were identified by mNGS alone.
Delve Detect is the company's flagship testing service, providing comprehensive test results with a 48-hour turnaround time after sample receipt and access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts to review results in clinical context. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio.
About Delve Bio, Inc.
Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit www.delve.bio.
Amy Wong
Senior Director of Marketing and Business Development, Delve Bio
Media
42 North for Delve Bio
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES NEUROLOGY CLINICAL TRIALS RESEARCH SCIENCE
SOURCE: Delve Bio, Inc.
Copyright Business Wire 2025.
PUB: 04/07/2025 07:27 AM/DISC: 04/07/2025 07:26 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
a day ago
- Gizmodo
Smoking Weed and Eating Edibles Share This Surprising Health Risk
A new study has found a startling link between chronic cannabis use and increased risk of cardiovascular disease—regardless of whether you smoke it or consume edibles. The finding challenges commonly held beliefs about the health impacts of tetrahydrocannabinol (THC), which many see as a relatively harmless drug—especially when ingested. The study, published Wednesday, May 28 in the journal JAMA Cardiology, found that THC smokers suffer from significantly worse artery function than non-users. They observed the same effect in edible consumers, though their arteries were not as severely affected. In either case, vascular function was reduced by roughly half compared to those who do not use cannabis, according to a statement from the University of California, San Francisco. 'Scientifically, this THC result is really interesting but boy does it screw up the public health messaging,'' co-author Matt Springer, a cardiovascular researcher at UCSF, reportedly said to lead author and UCSF physician-scientist Leila Mohammadi when he saw the data. These results add to a growing body of evidence that suggests long-term weed use can lead to cardiovascular damage and life-threatening events such as heart attacks and strokes, though experts still lack consensus on its precise impacts. A 2024 study published in the Journal of the American Heart Association found that people who consume cannabis daily had a 25% increased risk of heart attack and a 42% increased risk of stroke compared to non-users. For this new study, researchers investigated how cannabis impacts vascular function. To isolate the effects of chronic cannabis use, they recruited 55 otherwise healthy adults aged 18 to 50 who did not use any form of nicotine and were not frequently exposed to secondhand smoke. These participants were sorted into three groups: marijuana smokers, edible users, and non-users. Those in the two cannabis user groups reported taking the drug at least three times per week, either exclusively through smoking or edibles. To assess the participants' vascular function, the researchers measured dilation of the brachial artery—located in the upper arm—to determine whether it could properly expand in response to increased blood flow. To that end, they used an inflatable forearm cuff to briefly block blood flow to the artery, then used ultrasound to measure its diameter before and after inflating the cuff. Matt Springer, a cardiovascular researcher at UCSF whose lab led the study, told Live Science that his test offers a 'window into the future.' When blood vessels cannot fully dilate, he said, the risk of heart attack and other poor cardiovascular outcomes increases. Participants who did not consume cannabis showed an average vessel dilation—represented as the percent change from the baseline measurement of artery diameter—of 10.4%. This value was significantly reduced among weed smokers and edible users, who showed an average vessel dilation of 6.0% and 4.6%, respectively. For reference, average values for brachial artery dilation in healthy individuals typically range from 8.0% to 15%. In a previous study, Springer's lab found similarly reduced levels of vessel dilation among e-cigarette and cigarette smokers. To better understand how THC causes this change, the researchers ran lab tests to determine how endothelial cells—which form the linings of blood vessels and release nitric oxide to trigger dilation—responded to the participants' blood samples. These tests revealed that the blood of chronic cannabis smokers inhibited nitric oxide production in the cells, which may explain why these participants showed reduced vessel dilation. This effect was not observed in edible consumers, however, suggesting that ingestible THC may impact arterial function via an entirely separate mechanism. Figuring out what that mechanism may be will require further research. What's more, subsequent studies will need to reproduce these findings in a larger population to validate the results. Within the last several years, cannabis use among U.S. adults has reached new heights, according to the NIH's National Institute on Drug Abuse. As such, investigating the health effects of THC is more important than ever before—especially as mounting evidence challenges perceptions of weed as a harmless high.
Associated Press
6 days ago
- Associated Press
Rosenman Symposium 2025 Brings National Healthcare Innovation to UCSF
A signature UCSF event, the symposium convenes top minds to address cost, equity, and the future of care 'Our theme this year was Healthcare in Harmony. Not because harmony is impossible, but because it's essential. When innovation, cost, and care are in sync, everyone benefits.'— Christine Winoto, Executive Director of the UCSF Rosenman Institute SAN FRANCISCO, CA, UNITED STATES, May 30, 2025 / / -- On May 20–21, the UCSF Rosenman Institute hosted the 9th Annual Rosenman Symposium at UCSF Mission Bay—two days of raw, candid, and solution-driven conversations on the future of healthcare. The Rosenman Institute at UCSF, one of the world's leading health sciences institutions, exists to convene, connect, and catalyze—bringing national voices together to inspire breakthrough solutions and foster lasting partnerships. UCSF faculty and leaders played central roles in helping shape the dialogue on cost, equity, and innovation. 'UCSF is a place where innovation, research, and care come together every day,' said Christine Winoto, Executive Director of the UCSF Rosenman Institute. 'This symposium reflects that spirit, connecting leaders from across the healthcare ecosystem so we can shape what's next together. Our theme this year was Healthcare in Harmony. Not because harmony is impossible, but because it's essential. When innovation, cost, and care are in sync, everyone benefits.' Discussions spanned a wide range of intersecting issues, including the $9 trillion forecast for U.S. healthcare spending, equity gaps, women's heart health, the future of cancer therapy and the cost, and behavioral health. Throughout, participants explored how to design healthcare that is not only innovative and cost-effective, but also inclusive, measurable, and accountable. The Rosenman Institute brought forward impactful topics and created space for participants to think differently. By challenging assumptions and surfacing new perspectives, the symposium encouraged everyone, from entrepreneurs and UCSF Health leaders to broader healthcare industry decision makers and stakeholders, to approach problems in new ways. The goal: to spark solutions that reshape how we address the most pressing issues in healthcare. The Rosenman Institute, together with Blue Shield of California and Kaiser Permanente, also honored Dr. Sandra Hernández, President and CEO of the California Health Care Foundation, with the 2025 UCSF Healthcare Impact Award, recognizing her decades-long leadership in advancing equity, public accountability, and access across the state. The symposium offered a unique opportunity to connect with healthcare stakeholders from payers and providers to investors, clinician-researchers, and innovators. As always, the Rosenman Symposium had no press, creating a rare space for honesty and breakthrough thinking. How Leaders Described the Symposium: 'The Rosenman Symposium is an outstanding opportunity to focus on the triangle of healthcare: quality, access, and affordability. Must we pick two, or is there a world where we can have all three? At Rosenman, the conversation is all about building a healthcare system that delivers on all three.' — Tom Insel, MD, Co-Founder Vanna Health and Benchmark Health, Former NIMH Director 'Each presentation was deeply empowering. I left the event better informed and more motivated to advocate for change.' — Karin Bartley, Blue Shield of California 'This is a symposium of ideas and innovation that brings together a diverse group of individuals who are at the forefront of what healthcare can be. It is the perfect place to be inspired, wowed, encouraged, and come out on the other end knowing that we have a lot of work to do and that with this community and this level of engagement there is a path forward.' — Fumi Mitsuishi, MD, Chief of Service, Psychiatry, ZSFG & Vice Chair for ZSFG, Professor of Medicine, UCSF 'The Rosenman Symposium is truly unique – it seamlessly balances deep policy insight with cutting-edge digital health innovation. The invite-only mix of top healthcare leaders sparked candid, strategic conversations I haven't experienced anywhere else.' — Lindsay Aspegren, Co-founder, North Coast Technology Investors Herminio Neto UCSF Rosenman Institute [email protected] Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
6 days ago
- Yahoo
Smoking marijuana and eating cannabis gummies both linked to dangerous health risk, study finds
Long-term cannabis use in any form has been linked to a greater risk of heart disease. In a new study, researchers at UC San Francisco determined that eating edible cannabis, such as gummies, has the same impact on cardiovascular risk as smoking marijuana. The risk stems from reduced blood vessel function, according to the study, which was published in JAMA Cardiology on May 28. Heavy Cannabis Use Could Pose This Threat To The Brain The study included 55 people between 18 and 50 years of age who were "outwardly healthy." The participants were divided into three groups: those who regularly smoked marijuana, those who ate edibles containing THC (tetrahydrocannabinol), and those who didn't use cannabis, according to a UCSF press release. Read On The Fox News App The cannabis users had been consuming the substance at least three times weekly for at least one year. On average, the smokers had the habit for 10 years, while those consuming edibles had been doing so for five years, the release noted. In September 2024, the participants underwent testing to determine how well their blood vessels functioned and whether the cells lining the blood vessels were affected. Dementia Risk Connected To Cannabis-related Hospital Visits, Says Study All cannabis users were found to have "decreased vascular function," comparable to those who smoke tobacco. Their blood vessel function was roughly half compared to those who did not use cannabis. This side effect has been linked to a higher risk of heart attack, high blood pressure and other cardiovascular conditions, the researchers noted. The participants who smoked marijuana were also found to have changes in their blood serum that harmed cells lining their blood vessels and lymphatic vessels, an effect that was not seen in those who ate edible cannabis. The researchers noted that while smoking marijuana and consuming edibles both affect vascular function, they likely do so for different reasons. Shingles Vaccine Has Unexpected Effect On Heart Health "Chronic cannabis smoking and THC ingestion were associated with endothelial dysfunction [impaired functioning of the endothelial cells lining the inside of blood vessels] similar to that observed in tobacco smokers, although apparently occurring via distinct mechanisms," the researchers wrote. "This study enhances the understanding of the potential risks to vascular health linked to cannabis use and provides more evidence that cannabis use is not benign." Dr. Bradley Serwer, a Maryland-based cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company that offers cardiovascular and anesthesiology services to hospitals nationwide, said he was not surprised by the study's findings. "We have known that the chronic use of THC-containing compounds can have negative health consequences — this study just reaffirms those prior studies," Serwer, who was not involved in the UCSF research, told Fox News Digital. The study did have some limitations. "Variability in cannabis strains complicates standardization," the researchers wrote. "Self-reported cannabis use may introduce recall bias; thus, participants were queried at multiple points: in the online survey, at the eligibility interview and before each visit." It was also challenging to determine whether blood vessel function could have also been affected by lifestyle factors like stress, caffeine and secondhand smoke exposure, they noted. Serwer pointed out that this was a "very small" study of only 55 people, all living in the San Francisco Bay area. "The study did not allow for variability in the different strains of cannabis, and they used a self-reporting survey, which can be under- or over-reported," he told Fox News Digital. "They looked for physiologic endpoints and not hard endpoints, such as heart attacks, strokes or death. We have to infer that the physiologic endpoints would result in cardiovascular events." Click Here To Sign Up For Our Health Newsletter The cardiologist said he agreed, however, with the conclusion that cannabis use is "not benign." "Chronic use does have potential cardiovascular risks," he warned. "There are therapeutic uses of cannabis, and the decision to use or avoid it should be made with all benefits and risks in mind." In general, Serwer said he cautions all of his patients to avoid any unnecessary cardiac risks. "As clinicians, we must weigh the benefits and the risks of a medicine/drug or intervention," he said. "If the risks outweigh the benefits, it should be avoided." For more Health articles, visit The study was funded mainly by the National Institute on Drug Abuse; the California Department of Cannabis Control; the California Tobacco-Related Disease Program; the National Heart, Lung, and Blood Institute; and the FDA Center for Tobacco Products. Fox News Digital reached out to cannabis industry organizations requesting article source: Smoking marijuana and eating cannabis gummies both linked to dangerous health risk, study finds
